Integrating genetic approaches into the discovery of anticancer drugs.
about
Warburg effect and translocation-induced genomic instability: two yeast models for cancer cellsThe topoisomerase-related function gene TRF4 affects cellular sensitivity to the antitumor agent camptothecinThe Rad51 paralog Rad51B promotes homologous recombinational repairTargeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugsBRCAness: finding the Achilles heel in ovarian cancerViruses associated with human cancerSystematic quantification of gene interactions by phenotypic array analysisEnhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitorsTumor-Derived Cell Lines as Molecular Models of Cancer PharmacogenomicsSynthetic lethality and cancer: cohesin and PARP at the replication forkSynthetic lethal screens as a means to understand and treat MYC-driven cancersStructure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive reviewThe role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapyA phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - AnSubstrate specificity and sequence-dependent activity of the Saccharomyces cerevisiae 3-methyladenine DNA glycosylase (Mag)Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancerSynthetic lethality in lung cancer and translation to clinical therapiesDrugging the addict: non-oncogene addiction as a target for cancer therapyRAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug actionEstablishment of a chemical synthetic lethality screen in cultured human cellsAn evolutionarily conserved synthetic lethal interaction network identifies FEN1 as a broad-spectrum target for anticancer therapeutic developmentThe Validation of Nematode-Specific Acetylcholine-Gated Chloride Channels as Potential Anthelmintic Drug TargetsThe Hippo Pathway Targets Rae1 to Regulate Mitosis and Organ Size and to Feed Back to Regulate Upstream Components Merlin, Hippo, and WartsSystematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1Chromosome instability and defective recombinational repair in knockout mutants of the five Rad51 paralogsMonitoring dynamics of single-cell gene expression over multiple cell cyclesPancreatic cancer.Defining interacting partners for drug discovery.Genetic synthetic lethality screen at the single gene level in cultured human cells.shRNA libraries and their use in cancer genetics.Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions.Composite synthetic lethal identification of membrane traffic inhibitors.Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells.Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.Methodological approaches in application of synthetic lethality screening towards anticancer therapyHuman synthetic lethal inference as potential anti-cancer target gene detectionBiomarker Validation for Aging: Lessons from mtDNA Heteroplasmy Analyses in Early Cancer Detection.Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA deliveryDNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1
P2860
Q21129304-3EF21217-2F70-4CCF-8F7E-3BC5F7C950C0Q22009054-7193310C-152B-4E89-B67F-BF6B789712A6Q24551864-0AD745EE-E8EC-4B45-A12B-99931C53DBEDQ24610287-25EF4495-B62E-440A-8A8A-8591F959F11EQ24630872-3B17686C-D62B-4950-A204-C0459676A7C9Q24653900-AF689C3B-F8A5-4968-90D5-0D8526ACD5D2Q24805253-218C4FFE-2B8E-4AFB-BEB7-9F23590CE860Q26768267-F7295D69-8C6D-4466-A057-B6E2B8E84599Q26801410-BF510E11-901A-4F1A-B357-6F1FD774010BQ26991603-2CBC1639-DDF7-47AA-80C0-AE238817AC6FQ27006010-CBF08D12-D7F0-480D-890E-12064F369095Q27008867-E9F7D893-B059-4D53-8675-EE4681248FBBQ27010084-D4DB6680-4068-4821-9E45-103CECA41B40Q27302763-90ED0EB6-BE38-4341-9855-C0AC799BD8BBQ27937334-4D01A3FD-2322-47DD-8512-E03887C07E98Q28066320-97FB04C6-41DB-4086-8589-82A3D8BB061DQ28072904-289311BA-ABAB-4CC1-8FDA-3FFF55FF82F8Q28079559-41EFA572-C98F-4227-A43C-71380634B13DQ28260541-D6888DC3-CB5A-4278-8591-F4DFA4DBB7E6Q28343624-6C4A5000-5BF5-4750-AC76-31B30B5E3670Q28346052-DC6AAABD-E1FD-446C-B7BD-70C979B02693Q28485395-1803FCFF-B1A2-4314-8965-7C5D058AD3CDQ28548328-A1A8F875-1EC1-449E-B8FC-A96F6781C2FBQ28553403-BE31C9E6-5E35-4372-BCD9-3960BF82BBE1Q29617043-FE8FBD17-6D36-48DA-864D-E399CFAD29FFQ29622881-00A3891E-AA12-4FE9-AA48-BEE188B9A9E3Q30478425-8D39A514-07AC-4531-B234-026C73884E13Q30490247-3D2B5EC2-FDCF-43E7-96EE-29926AEB3688Q31136920-5B5E378C-D148-4718-955A-0AB22681FDB1Q31994489-36E9D350-6370-4C1C-A004-660ED550E108Q33255055-3C28FDA1-10F1-442D-A36C-0E901D541544Q33258367-E70ABF19-9BE1-410E-B065-94E00BCDAB7AQ33280876-E5E11B05-A694-4777-9E63-768E17553757Q33324778-CFBF1D0B-794E-4A01-BA09-1FCA0E3397AAQ33415400-840C631A-5326-4ADD-A55F-30D98A68195FQ33421697-7073C24A-7435-4E70-AB68-1027D73A5E4FQ33518904-F12B804F-C927-46D7-9599-D9B4822ED357Q33520448-F2A75D82-A088-463A-9801-260DEFF34DAAQ33587012-E557202E-4804-4627-92E7-4187D4ACC620Q33754229-6F45EB7F-1F61-4CAC-A6A2-30D9C63EC355
P2860
Integrating genetic approaches into the discovery of anticancer drugs.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Integrating genetic approaches into the discovery of anticancer drugs.
@en
type
label
Integrating genetic approaches into the discovery of anticancer drugs.
@en
prefLabel
Integrating genetic approaches into the discovery of anticancer drugs.
@en
P2093
P1433
P1476
Integrating genetic approaches into the discovery of anticancer drugs.
@en
P2093
Hartwell LH
Roberts CJ
Szankasi P
P304
P356
10.1126/SCIENCE.278.5340.1064
P407
P577
1997-11-01T00:00:00Z